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Cocrystals have recently gained attention as attractive alternate solid forms for 
drug development. A pharmaceutical cocrystal is a single crystalline homogenous 
phase consisting of a drug molecule and ligand i.e. cocrystal former that is excipient 
or another drug molecule [1,2]. The different components in the cocrystal are neutral 
in nature when compared to salts that have ionized components. [1,2,3]. The 
components in a cocrystal exist in a definite stoichiometric ratio, and assemble via 
non-covalent interactions such as hydrogen bonds, ionic bonds, π-π or van der Waals 
interactions. Cocrystals thus possess different composition and structure when 
compared to the crystals of parent components. 
Examples in the preceding section show that cocrystallization alters the 
molecular interactions and composition of pharmaceutical materials. As such one can 
expect changes in physico-chemical properties such as chemical stability [4], 
hygroscopicity [5], dissolution rates and solubility [6] compressibility [6] due to 
cocrysallization of pharmaceutical materials.  
To formulate Pharmaceutical Cocrystal(s) will be used two drugs which 
proton-acceptor and/ or proton-donor functional groups can form syntons toward H-
bonding with appropriate to them functional group encompassed in their structure. 
The selection of drug models will be done according to their performance of dual or 
complementary pharmacological responds in therapy. The formulated cocrystal of two 
drug molecules will present New Chemical Entity (NCE) that offer opportunity to be 
cover with patent protection and further to be used as single Active Pharmaceutical 
ingrediant in combo i.e. fixed pharmaceutical formulation that perform dual action in 
therapy. 
Research methodology encompasses the drug cocrystal screening toward 
applying procedures for crystallization, and analytical techniques for characterization 
of formed cocrystal in solid state and in solution, respectively. 
 Keywords: drug cocrystals, crystallization, solid state characterization 
 
 
 
 
 
 
 
 
 
 
Workshop  – Skopje, March 2011 
References: 
1. Rodríguez-Hornedo, N.; Nehm, S. J.; Jayasankar, A. Cocrystals: Design, 
Properties and Formation Mechanisms. In Encyclopedia of Pharmaceutical 
Technology, 3rd ed.; Swarbrick, J., Eds.; Informa Health Care: 2006; pp 615-
635. 
2. Vishweshwar, P.; McMahon, J. A.; Bis, J. A.; Zaworotko, M. J. 
Pharmaceutical Co-Crystals. J. Pharm. Sci. 2006, 95, 499-516 
3. Aakeroy, C. B.; Fasulo, M. E.; Desper, J. Cocrystal or Salt: Does It Really 
Matter? Mol. Pharm. 2007, 4, 317-322.  
4. Nehm, S. J.; Rodríguez-Spong, B.; Rodríguez-Hornedo, N. Phase Solubility 
Diagrams of Cocrystals Are Explained by Solubility Product and Solution 
Complexation. Cryst. Growth Des. 2006, 6, 592-600. 
5. Reddy, L. S.; Bethune, S. J.; Kampf, J. W.; Rodríguez-Hornedo, N. Cocrystals 
and Salts of Gabapentin: Cryst. Growth Des. 2008, 
6. Sun, C. C.; Hou, H. Improving Mechanical Properties of Caffeine and Methyl 
Gallate Crystals by Cocrystallization. Cryst. Growth Des. 2008, 8, 1575-1579 
